Search

Your search keyword '"Calaminus, G"' showing total 595 results
Start Over Author "Calaminus, G"
595 results on '"Calaminus, G"'

1. VersKiK: Study protocol of an observational registry-based study on the current state of follow-up care and adherence to follow-up guidelines after cancer in childhood or adolescence

Author

Aleshchenko, E., Apfelbacher, C., Baust, K., Calaminus, G., Droege, P., Glogner, J., Horenkamp-Sonntag, D., Ihle, P., Kaatsch, P., Klein, M., Kloppe, T., Kuepper-Nybelen, J., Langer, T., Luepkes, C., Marschall, U., Meier, I., Merzenich, H., Spix, C., Swart, E., and Trocchi, P.

Published
2023
Full Text
View/download PDF

2. Long-term care, care needs and wellbeing of individuals after cancer in childhood or adolescence (VersKiK): study protocol of a large scale multi-methods non-interventional study

Author

Aleshchenko, E., Swart, E., Spix, C., Voigt, M., Trocchi, P., Langer, T., Calaminus, G., Baust, K., Glogner, J., Ihle, P., Küpper-Nybelen, J., Lüpkes, C., Kloppe, T., Horenkamp-Sonntag, D., Meier, I., Marschall, U., Dröge, P., Klein, M., Weiss, A., and Apfelbacher, C.

Published
2022
Full Text
View/download PDF

3. Kardiologische Spätfolgen bei Überlebenden nach einer Krebserkrankung im Kindes- oder Jugendalter - Ergebnisse der VersKiK-Studie

Author

Merzenich, H, Trocchi, P, Spix, C, Alshchenko, E, Lüpkes, C, Ihle, P, Küpper-Nybelen, J, Calaminus, G, Baust, K, Langer, T, Horenkamp-Sonntag, D, Meier, I, Dröge, P, Ruhnke, T, Marschall, U, Klein, M, Ronckers, CM, Swart, E, Merzenich, H, Trocchi, P, Spix, C, Alshchenko, E, Lüpkes, C, Ihle, P, Küpper-Nybelen, J, Calaminus, G, Baust, K, Langer, T, Horenkamp-Sonntag, D, Meier, I, Dröge, P, Ruhnke, T, Marschall, U, Klein, M, Ronckers, CM, and Swart, E

Published
2024

4. Hörschäden, Krankheiten der Schilddrüse und sonstiger endokrinen Drüsen bei Langzeit-Überlebenden einer Krebserkrankung im Kindes- oder Jugendalter - Ergebnisse der VersKiK-Studie

Author

Trocchi, P, Merzenich, H, Spix, C, Alshchenko, E, Lüpkes, C, Ihle, P, Küpper-Nybelen, J, Calaminus, G, Baust, K, Langer, T, Gebauer, J, Horenkamp-Sonntag, D, Dröge, P, Ruhnke, T, Marschall, U, Klein, M, Ronckers, CM, Swart, E, Trocchi, P, Merzenich, H, Spix, C, Alshchenko, E, Lüpkes, C, Ihle, P, Küpper-Nybelen, J, Calaminus, G, Baust, K, Langer, T, Gebauer, J, Horenkamp-Sonntag, D, Dröge, P, Ruhnke, T, Marschall, U, Klein, M, Ronckers, CM, and Swart, E

Published
2024

6. VersKiK: Evaluation der medizinischen Versorgung bei Personen nach einer Krebserkrankung im Kindes- oder Jugendalter mit GKV-Abrechnungsdaten

Author

Trocchi, P, Merzenich, H, Ronckers, C, Spix, C, Ihle, P, Küpper-Nybelen, J, Lüpkes, C, Horenkamp-Sonntag, D, Dröge, P, Ruhnke, T, Baust, K, Calaminus, G, Langer, T, Aleshchenko, E, Swart, E, Trocchi, P, Merzenich, H, Ronckers, C, Spix, C, Ihle, P, Küpper-Nybelen, J, Lüpkes, C, Horenkamp-Sonntag, D, Dröge, P, Ruhnke, T, Baust, K, Calaminus, G, Langer, T, Aleshchenko, E, and Swart, E

Published
2024

8. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment †

Author

Whelan, JS, Bielack, SS, Marina, N, Smeland, S, Jovic, G, Hook, JM, Krailo, M, Anninga, J, Butterfass-Bahloul, T, Böhling, T, Calaminus, G, Capra, M, Deffenbaugh, C, Dhooge, C, Eriksson, M, Flanagan, AM, Gelderblom, H, Goorin, A, Gorlick, R, Gosheger, G, Grimer, RJ, Hall, KS, Helmke, K, Hogendoorn, PCW, Jundt, G, Kager, L, Kuehne, T, Lau, CC, Letson, GD, Meyer, J, Meyers, PA, Morris, C, Mottl, H, Nadel, H, Nagarajan, R, Randall, RL, Schomberg, P, Schwarz, R, Teot, LA, Sydes, MR, Bernstein, M, Pickering, James, Joffe, Nicola, Kevric, Matthias, Sorg, Benjamin, Villaluna, Doojduen, Wang, Caroline, Perisoglou, Martha, Trani, Leonardo, Potratz, Jenny, Carrle, Dorothe, Wilhelm, Miriam, Zils, Katja, and Teske, Carmen

Subjects
Pediatric, Cancer, Clinical Trials and Supportive Activities, Clinical Research, Pediatric Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adolescent, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Child, Cisplatin, Combined Modality Therapy, Doxorubicin, Etoposide, Female, Humans, Ifosfamide, Interferon-alpha, Male, Methotrexate, Neoadjuvant Therapy, Osteosarcoma, Polyethylene Glycols, Quality of Life, Research Design, Young Adult, EURAMOS collaborators, international collaboration, osteosarcoma, randomised controlled trial, trial conduct, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundFour international study groups undertook a large study in resectable osteosarcoma, which included two randomised controlled trials, to determine the effect on survival of changing post-operative chemotherapy based on histological response.Patients and methodsPatients with resectable osteosarcoma aged ≤40 years were treated with the MAP regimen, comprising pre-operatively of two 5-week cycles of cisplatin 120 mg/m(2), doxorubicin 75 mg/m(2), methotrexate 12 g/m(2) × 2 (MAP) and post-operatively two further cycles of MAP and two cycles of just MA. Patients were randomised after surgery. Those with ≥10% viable tumour in the resected specimen received MAP or MAP with ifosfamide and etoposide. Those with

Published
2015

10. ZNS-Tumoren

Author

Fleischhack, G., Rutkowski, S., Pfister, S., Pietsch, T., Tippelt, S., Warmuth-Metz, M., Bison, B., van Velthoven-Wurster, V., Messing-Jünger, M., Kortmann, R.-D., Timmermann, B., Slavc, I., Witt, O., Gnekow, A. K., Hernáiz Driever, P., Kramm, C., Benesch, M., Frühwald, M. C., Hasselblatt, M., Müller, H. L., Sörensen, N., Kordes, U. R., Calaminus, G., Niemeyer, Charlotte, editor, and Eggert, Angelika, editor

Published
2018
Full Text
View/download PDF

16. Comprehensive assessments and related interventions to enhance the long-term outcomes of child, adolescent and young adult cancer survivors – presentation of the CARE for CAYA-Program study protocol and associated literature review

Author

Salchow, J., Mann, J., Koch, B., von Grundherr, J., Jensen, W., Elmers, S., Straub, L. A., Vettorazzi, E., Escherich, G., Rutkowski, S., Dwinger, S., Bergelt, C., Sokalska-Duhme, M., Bielack, S., Calaminus, G., Baust, K., Classen, C. F., Rössig, C., Faber, J., Faller, H., Hilgendorf, I., Gebauer, J., Langer, T., Metzler, M., Schuster, S., Niemeyer, C., Puzik, A., Reinhardt, D., Dirksen, U., Sander, A., Köhler, M., Habermann, J. K., Bokemeyer, C., and Stein, A.

Published
2020
Full Text
View/download PDF

19. Platin-related Hearing Loss: Further Results from PanCareLIFE

Author

Parfitt, R, Matulat, P, Byrne, J, Langer, T, Deuster, D, Hesping, A, Clemens, E, Kaatsch, P, Grabow, D, O'Brien, K, Kaiser, M, Spix, C, Kremer, LC, van Dulmen-den Broeder, E, Calaminus, G, Baust, K, Kuehni, C, Weiss, A, Strebel, S, Kuonen, R, Elsner, S, Haupt, R, Garré, ML, Kepak, T, Kapakova, K, Falck Winther, J, Kenborg, L, Rechnitzer, C, Hasle, H, Kruseova, J, Luks, A, Lackner, H, Beilack, S, Hecker-Nolting, S, Beck, JD, van den Heuvel-Eibrink, M, Zolk, O, am Zehnhoff-Dinnesen, A, PanCareLIFE Consortium, Parfitt, R, Matulat, P, Byrne, J, Langer, T, Deuster, D, Hesping, A, Clemens, E, Kaatsch, P, Grabow, D, O'Brien, K, Kaiser, M, Spix, C, Kremer, LC, van Dulmen-den Broeder, E, Calaminus, G, Baust, K, Kuehni, C, Weiss, A, Strebel, S, Kuonen, R, Elsner, S, Haupt, R, Garré, ML, Kepak, T, Kapakova, K, Falck Winther, J, Kenborg, L, Rechnitzer, C, Hasle, H, Kruseova, J, Luks, A, Lackner, H, Beilack, S, Hecker-Nolting, S, Beck, JD, van den Heuvel-Eibrink, M, Zolk, O, am Zehnhoff-Dinnesen, A, and PanCareLIFE Consortium

Abstract

Background: Cisplatin and Carboplatin are widely-used in paediatric cancer treatment. Sensorineural hearing loss (SNHL) is one long-term side-effect. This study utilises a larger sample than previous research in order to investigate risk-factors for platin-related ototoxicity.Material and methods: Retrospective audiological and treatment data of 997 children and adolescents were gathered with the involvement of 18 pan-European institutions in 7 different countries as part of the PanCareLIFE consortium. Prior hearing loss was excluded. Conductive hearing losses were excluded where identified.Results: Prevalence rates of clinically-significant hearing loss (=> 2b Münster Classification) after treatment were 49 % (Cisplatin) and 15 % (Carboplatin). Where Cisplatin was administered prior to Carboplatin, prevalence rose to 76 %. Frequencies in the high and extended high-frequency range were predominantly affected, with mean threholds between 25-35 dB HL. Mean thresholds at frequencies below 3 kHz remained lower than 20 dB HL. No significant air-bone gap was apparent.50 % of clinically-significant hearing losses began within 3 years of start of treatment (Kaplan-Meier analysis). No significant difference in time-to-onset at different frequencies within the standard range was found. Further analyses, including multifactorial analysis to account for platin doses, presence of cranial radiotherapy, age and date of diagnosis will be conducted.Discussion: Analysis of this large sample was able to confirm the significant risk of SNHL posed by platin-based chemotherapeutics. Some quantitative and qualitative variation were present in this multi-centre retrospective dataset.Conclusion: This large sample confirms that platin-based chemotherapeutics, especially cisplatin, pose a significant risk of SNHL and underlines the necessity of audiological monitoring during and after end of chemotherapy.Acknowledgement: This work was supported by the PanCareLIFE consortium that has received

Published
2023

22. Das CARE-for-CAYA-Programm: Präventionskonzept für junge Menschen nach Krebserkrankung

Author

Quidde, J., Koch, B., Salchow, J., Jensen, W., von Grundherr, J., Escherich, G., Rutkowski, S., Schulz-Kindermann, F., Bergelt, C., Bokemeyer, C., Sokalska-Duhme, M., Bielack, S., Calaminus, G., Classen, C. F., Rössig, C., Faber, J., Faller, H., Hilgendorf, I., Langer, T., Metzler, M., Schuster, S., Niemeyer, C., Pierce, A., Reinhardt, D., Sander, A., Köhler, M., and Stein, A.

Published
2017
Full Text
View/download PDF

24. VersKiK – Versorgung, Versorgungsbedarf und Versorgungsbedürfnisse von Personen nach einer Krebserkrankung im Kindes- oder Jugendalter: Studiendesign

Author

Aleshchenko, E, Trocchi, P, Swart, E, Spix, C, Langer, T, Baust, K, Calaminus, G, Ihle, P, Küpper-Nybelen, J, Dröge, P, Horenkamp-Sonntag, D, Marschall, U, Klein, M, Lüpkes, C, and Apfelbacher, C

Subjects
ddc: 610, Medicine and health
Abstract

About 2,100 children and young adults below age 18 are diagnosed with cancer in Germany each year [ref:1]. Around two-thirds of all childhood cancer survivors suffer from at least one late effect in the course of their lives, directly or indirectly associated with the cancer itself or its [for full text, please go to the a.m. URL]

Published
2022
Full Text
View/download PDF

26. Keimzelltumoren

Author

Göbel, U., Calaminus, G., Schneider, D. T., Schmoll, Hans-Joachim, editor, Höffken, Klaus, editor, and Possinger, Kurt, editor

Published
2006
Full Text
View/download PDF

27. Zusammenführung von Daten aus dem Deutschen Kinderkrebsregister (DKKR) mit Routinedaten aus gesetzlichen Krankenkassen: methodische Aspekte aus der VersKiK-Studie

Author

Trocchi, P, additional, Swart, E, additional, Aleshchenko, E, additional, Spix, C, additional, Voigt, M, additional, Lüpkes, C, additional, Ihle, P, additional, Küpper-Nybelen, J, additional, Meier, I, additional, Horenkamp-Sonntag, D, additional, Dröge, P, additional, Marschall, U, additional, Klein, M, additional, Calaminus, G, additional, Baust, K, additional, Langer, T, additional, and Apfelbacher, C, additional

Published
2022
Full Text
View/download PDF

28. Management of malignant dysgerminoma of the ovary

Author

Arndt, T., Taube, E.T., Deubzer, H.E., Rothe, K., Calaminus, G., Sehouli, J., and Pietzner, K.

Subjects
Cancer Research
Abstract

The evolution of treatment for malignant ovarian germ cell tumors has been one of the most successful in the history of gynecologic oncology, with dysgerminoma as the most common type of malignant ovarian germ cell tumors. Since the introduction of platinum-based chemotherapy in the 1980s, 5-year survival rates for early-stage dysgerminomas have been close to 100%, and as high as 98% for advanced stages. Despite this remarkable achievement, many questions remain in routine treatment. By performing a literature review, we aim to highlight both the current treatment of malignant dysgerminoma and unanswered questions in the modern management of this disease. These issues relate firstly to surgical therapy, such as the role of routine omentectomy and lymphadenectomy, the value of complete surgical resection, and the possibility of fertility-sparing surgery. Second, chemotherapy and the question of the possibility of de-escalation in early stages and the potential of neoadjuvant chemotherapy in advanced stages will be addressed. Finally, a brief overview of the current developments of new drug treatment regimens will be given.

Published
2022

29. Entschlüsselung molekularer und (epi-)genetischer Mechanismen während der Differenzierung von Embryonalkarzinomen zu Dottersacktumoren

Author

Kotthoff, M, Wruck, W, Adjaye, JA, Nettersheim, D, Skowron, M, Bremmer, F, Fichtner, A, Schönberger, S, Calaminus, G, Vokuhl, C, Pfister, D, Heidenreich, A, Albers, P, Kotthoff, M, Wruck, W, Adjaye, JA, Nettersheim, D, Skowron, M, Bremmer, F, Fichtner, A, Schönberger, S, Calaminus, G, Vokuhl, C, Pfister, D, Heidenreich, A, and Albers, P

Published
2022

30. Late mortality reduction among survivors of germ cell tumors in childhood and adolescence in Europe: A report from the PanCareSurFup cohort

Author

Trama, A, Bernasconi, A, Botta, L, Byrne, J, Grabow, D, Reulen, R, Calaminus, G, Terenziani, M, Trama, Annalisa, Bernasconi, Alice, Botta, Laura, Byrne, Julianne, Grabow, Desiree, Reulen, Raoul C, Calaminus, Gabriele, Terenziani, Monica, Trama, A, Bernasconi, A, Botta, L, Byrne, J, Grabow, D, Reulen, R, Calaminus, G, Terenziani, M, Trama, Annalisa, Bernasconi, Alice, Botta, Laura, Byrne, Julianne, Grabow, Desiree, Reulen, Raoul C, Calaminus, Gabriele, and Terenziani, Monica

Abstract

Background: Data on late mortality from pediatric germ cell tumors (GCTs) are limited to small case series. Our population-based study aimed to investigate excess risk of death in survivors of GCT in childhood and adolescence, whether long-term mortality changed over time and by period of diagnosis. Methods: The PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies (PanCareSurFup) cohort includes 2773 five-year survivors diagnosed under 21 years of age with gonadal and extragonadal GCT (from 1940 to 2008). We calculated standardized mortality ratios (SMRs) and absolute excess risks (AERs). We fitted a Cox's model to assess the impact of treatment period. We estimated 10-year survival and calculated average percentage changes between periods of diagnosis (1970–1979, 1980–1989, 1990–1999) to assess whether late mortality decreased. Results: GCT survivors had an almost four-fold excess risk of dying compared to general population. The risk of death for patients treated after 1980 was nearly halved compared to patients treated before 1980. Survivors diagnosed in 1990–1999 had a 10-year survival rate of 99%, which was 2.4% and 1.1% higher than for patients treated in 1970–1979 and 1980–1989, respectively. Conclusions: This is the largest population-based study in Europe and showed a decrease in long-term mortality for survivors of GCTs in childhood and adolescence over the last decades. After the introduction of platinum compound in 1980, which is a paradigm of success compared to the previous treatments, no major changes in drug therapies have been made to treat GCTs in the last 40 years. However, GCT survivors maintain an excessive risk of death that requires long-term care.

Published
2022

31. Merging Data from the German Childhood Cancer Registry (DKKR) with Routine Data from Statutory Health Insurance Companies: methodological Aspects from the VersKiK Study

Author

Trocchi, P., Swart, E., Aleshchenko, E., Spix, C., Voigt, M., Luepkes, C., Ihle, P., Kuepper-Nybelen, J., Meier, I, Horenkamp-Sonntag, D., Droege, P., Marschall, U., Klein, M., Calaminus, G., Baust, K., Langer, T., Apfelbacher, C., Trocchi, P., Swart, E., Aleshchenko, E., Spix, C., Voigt, M., Luepkes, C., Ihle, P., Kuepper-Nybelen, J., Meier, I, Horenkamp-Sonntag, D., Droege, P., Marschall, U., Klein, M., Calaminus, G., Baust, K., Langer, T., and Apfelbacher, C.

Published
2022

32. Essential medicines for childhood cancer in Europe: a pan-European, systematic analysis by SIOPE

Author

Maria, O, Eva, B, Pamela R, K, Olga, K, Marko, O, Reineke A, S, Gilles, V, Achini, F, Balduzzi, A, Beck Popovic, M, Beishuizen, A, Bergamaschi, L, Biondi, A, Bourdeaut, F, Braicu, E, Brok, J, Brugières, L, Burke, A, Calaminus, G, Casanova, M, Choucair, M, Cleirec, M, Corbaciouglu, S, Genoveva Correa Llano, M, De Rojas, T, Domínguez Pinilla, N, Elmaraghi, C, Ferrari, A, Fossa, A, Gaspar, N, Herold, N, Karapiperi, K, Karu, M, Kjærsgaar, M, Knörr, F, Koenig, C, Kranjcec, I, Krawczyk, M, Lehmberg, K, Lehrnbecher, T, Lunesink, M, Massano, D, Matijasic, N, Merks, H, Metzler, M, Michalski, A, Minkov, M, Morland, B, Niktoreh, N, Oltenau, E, Orbach, D, Owens, C, Papachristidou, S, Pasqualini, C, Pavlovic, M, Perez Albert, P, Poyer, F, Radulovic, I, Reinhardt, D, Rebelo, J, Roser, E, Russo, I, Scheinemann, K, Schindera, C, Schrappe, M, Sehested, A, Sehouli, J, Spreafico, F, J Strauss, S, Stutterheim, J, Svojgr, K, Tzotzola, V, Van Ewijk, R, Verschuur, A, Vora, A, Woessmann, W, Zajac-Spychala, O, Zwaan, M, Otth, Maria, Brack, Eva, Kearns, Pamela R, Kozhaeva, Olga, Ocokoljic, Marko, Schoot, Reineke A, Vassal, Gilles, Federica Achini, Adriana Balduzzi, Maja Beck Popovic, Auke Beishuizen, Luca Bergamaschi, Andrea Biondi, Franck Bourdeaut, Elena Braicu, Jesper Brok, Laurence Brugières, Amos Burke, Gabriele Calaminus, Michela Casanova, Marie-Louise Choucair, Morgane Cleirec, Selim Corbaciouglu, Maria Genoveva Correa Llano, Teresa De Rojas, Nerea Domínguez Pinilla, Caroline Elmaraghi, Andrea Ferrari, Alexander Fossa, Nathalie Gaspar, Nikolas Herold, Kyriaki Karapiperi, Maarja Karu, Mimi Kjærsgaar, Fabian Knörr, Christa Koenig, Izabela Kranjcec, Malgorzata Krawczyk, Kai Lehmberg, Thomas Lehrnbecher, Maaike Lunesink, Davide Massano, Nuša Matijasic, Hans Merks, Markus Metzler, Anthony Michalski, Milen Minkov, Bruce Morland, Naghmeh Niktoreh, Elena Oltenau, Daniel Orbach, Cormac Owens, Smaragda Papachristidou, Claudia Pasqualini, Maja Pavlovic, Paula Perez Albert, Fiona Poyer, Ivana Radulovic, Dirk Reinhardt, Joana Rebelo, Eva Roser, Ida Russo, Katrin Scheinemann, Christina Schindera, Martin Schrappe, Astrid Sehested, Jalid Sehouli, Filippo Spreafico, Sandra J Strauss, Janine Stutterheim, Karel Svojgr, Vasiliki Tzotzola, Roelof Van Ewijk, Arnauld Verschuur, Ajay Vora, Willi Woessmann, Olga Zajac-Spychala, Michel Zwaan, Maria, O, Eva, B, Pamela R, K, Olga, K, Marko, O, Reineke A, S, Gilles, V, Achini, F, Balduzzi, A, Beck Popovic, M, Beishuizen, A, Bergamaschi, L, Biondi, A, Bourdeaut, F, Braicu, E, Brok, J, Brugières, L, Burke, A, Calaminus, G, Casanova, M, Choucair, M, Cleirec, M, Corbaciouglu, S, Genoveva Correa Llano, M, De Rojas, T, Domínguez Pinilla, N, Elmaraghi, C, Ferrari, A, Fossa, A, Gaspar, N, Herold, N, Karapiperi, K, Karu, M, Kjærsgaar, M, Knörr, F, Koenig, C, Kranjcec, I, Krawczyk, M, Lehmberg, K, Lehrnbecher, T, Lunesink, M, Massano, D, Matijasic, N, Merks, H, Metzler, M, Michalski, A, Minkov, M, Morland, B, Niktoreh, N, Oltenau, E, Orbach, D, Owens, C, Papachristidou, S, Pasqualini, C, Pavlovic, M, Perez Albert, P, Poyer, F, Radulovic, I, Reinhardt, D, Rebelo, J, Roser, E, Russo, I, Scheinemann, K, Schindera, C, Schrappe, M, Sehested, A, Sehouli, J, Spreafico, F, J Strauss, S, Stutterheim, J, Svojgr, K, Tzotzola, V, Van Ewijk, R, Verschuur, A, Vora, A, Woessmann, W, Zajac-Spychala, O, Zwaan, M, Otth, Maria, Brack, Eva, Kearns, Pamela R, Kozhaeva, Olga, Ocokoljic, Marko, Schoot, Reineke A, Vassal, Gilles, Federica Achini, Adriana Balduzzi, Maja Beck Popovic, Auke Beishuizen, Luca Bergamaschi, Andrea Biondi, Franck Bourdeaut, Elena Braicu, Jesper Brok, Laurence Brugières, Amos Burke, Gabriele Calaminus, Michela Casanova, Marie-Louise Choucair, Morgane Cleirec, Selim Corbaciouglu, Maria Genoveva Correa Llano, Teresa De Rojas, Nerea Domínguez Pinilla, Caroline Elmaraghi, Andrea Ferrari, Alexander Fossa, Nathalie Gaspar, Nikolas Herold, Kyriaki Karapiperi, Maarja Karu, Mimi Kjærsgaar, Fabian Knörr, Christa Koenig, Izabela Kranjcec, Malgorzata Krawczyk, Kai Lehmberg, Thomas Lehrnbecher, Maaike Lunesink, Davide Massano, Nuša Matijasic, Hans Merks, Markus Metzler, Anthony Michalski, Milen Minkov, Bruce Morland, Naghmeh Niktoreh, Elena Oltenau, Daniel Orbach, Cormac Owens, Smaragda Papachristidou, Claudia Pasqualini, Maja Pavlovic, Paula Perez Albert, Fiona Poyer, Ivana Radulovic, Dirk Reinhardt, Joana Rebelo, Eva Roser, Ida Russo, Katrin Scheinemann, Christina Schindera, Martin Schrappe, Astrid Sehested, Jalid Sehouli, Filippo Spreafico, Sandra J Strauss, Janine Stutterheim, Karel Svojgr, Vasiliki Tzotzola, Roelof Van Ewijk, Arnauld Verschuur, Ajay Vora, Willi Woessmann, Olga Zajac-Spychala, and Michel Zwaan

Abstract

Background: Shortages and unequal access to anticancer medicines for children and adolescents are a reality in Europe. The aim of the European Society for Paediatric Oncology (SIOPE) Essential Anticancer Medicines Project was to provide a list of anticancer medicines that are considered essential in the treatment of paediatric cancers to help ensure their continuous access to all children and adolescents with cancer across Europe. Methods: This pan-European project, done between Jan 20, 2020, and Feb 18, 2022, was designed to be a systematic collection and review of treatment protocols and strategies that are used to treat childhood cancer in Europe. We formed 16 working groups on the basis of paediatric cancer types, and which were based on the existing SIOPE Clinical Trial Groups. Workings groups consisted of representatives from the SIOPE Clinical Trial Groups, Young SIOPE members, and senior paediatric oncology experts. Each group collected existing treatment protocols that are used to treat the respective cancer types in Europe. Medicines from the standard group of each protocol were extracted. For medicines not on the WHO Essential Medicines List for children (EMLc) 2017, working groups did a literature search to determine whether the medicines should be defined as essential, promising, or neither essential nor promising. Each group provided an individual summary, and all medicines that were considered essential by at least one group were combined in a joint list. Findings: The working groups identified 73 treatment protocols used in Europe and defined 66 medicines as essential. For several newer medicines, such as kinase inhibitors or tisagenlecleucel, the supporting evidence was insufficient to consider them essential, so these medicines were defined as promising. 25 medicines were considered promising by at least one working group. 22 (33%) of the 66 essential and none of the promising medicines were included in the WHO EMLc 2017. The WHO EMLc 2021 included

Published
2022

34. Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study

Author

Clemens, Eva, Broer, Linda, Langer, Thorsten, Uitterlinden, André G., de Vries, Andrica C. H., van Grotel, Martine, Pluijm, Saskia F. M., Binder, Harald, Byrne, Julianne, Broeder, Eline van Dulmen-den, Crocco, Marco, Kaiser, Melanie, Kenborg, Line, Winther, Jeanette F., Rechnitzer, Catherine, Hasle, Henrik, van der Kooi, Anne-Lotte F., Kremer, Leontien C., van der Pal, Heleen, Parfitt, Ross, Deuster, Dirk, Matulat, Peter, Spix, Claudia, Tillmanns, Amelie, Tissing, Wim J. E., Maier, Lara, am Zehnhoff-Dinnesen, Antoinette, Zolk, Oliver, Kaatsch, P., Grabow, D., Campbell, H., O’Brien, K., Kremer, L.C.M., van Dulmen-den Broeder, E., van den Berg, M.H., van den Heuvel-Eibrink, M.M., Borgmann-Staudt, A., Kuehni, C.E., Haupt, R., Kepak, T., Berger, C., Winther, J.F., Kruseova, J., Calaminus, G., Baust, K., Dirksen, U., Kuehni, Claudia E., van den Heuvel-Eibrink, Marry M., Guided Treatment in Optimal Selected Cancer Patients (GUTS), Pediatric surgery, CCA - Cancer biology and immunology, Amsterdam Reproduction & Development (AR&D), Internal Medicine, Pediatrics, and Obstetrics & Gynecology

Subjects
Oncology, Male, Candidate gene, Internationality, Medizin, CHILDREN, VARIANTS, Neoplasms, TPMT, 610 Medicine & health, Child, SURVIVORS, Cumulative dose, Child, Preschool, Molecular Medicine, Sensorineural hearing loss, Female, 360 Social problems & social services, medicine.drug, medicine.medical_specialty, INDUCED HEARING-LOSS, Side effect, Adolescent, Single-nucleotide polymorphism, Antineoplastic Agents, PLATINUM CHEMOTHERAPY, ACYP2, Young Adult, Ototoxicity, Internal medicine, Genetics, medicine, Humans, Hearing Loss, Genetic Association Studies, Retrospective Studies, Pharmacology, Cisplatin, CHILDHOOD-CANCER, business.industry, Infant, Newborn, Genetic Variation, Infant, medicine.disease, COMT, REPLICATION, business
Abstract

Ototoxicity is a common side effect of platinum treatment and manifests as irreversible, high-frequency sensorineural hearing loss. Genetic association studies have suggested a role for SNPs in genes related to the disposition of cisplatin or deafness. In this study, 429 pediatric patients that were treated with cisplatin were genotyped for 10 candidate SNPs. Logistic regression analyses revealed that younger age at treatment (≤5 years vs >15 years: OR: 9.1; 95% CI: 3.8–21.5; P = 5.6 × 10−7) and higher cumulative dose of cisplatin (>450 vs ≤300 mg/m2: OR: 2.4; 95% CI: 1.3–4.6; P = 0.007) confer a significant risk of ototoxicity. Of the SNPs investigated, none of them were significantly associated with an increase of ototoxicity. In the meta-analysis, ACYP2 rs1872328 (OR: 3.94; 95% CI: 1.04–14.03; P = 0.04) and SLC22A2 rs316019 (OR: 1.46; 95% CI: 1.07–2.00; P = 0.02) were associated with ototoxicity. In order to increase the understanding of the association between SNPs and ototoxicity, we propose a polygenic model, which takes into account multiple interacting genes of the cisplatin pathway that together confer an increased risk of ototoxicity.

Published
2020

39. Evaluation of the perioperative and postoperative course of surgery of pineal germinoma according to the SIOP CNS GCT 96 trial

Author

Shabo, E, Calaminus, G, and Haberl, H

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Objective: CNS germinoma, being marker-negative, are diagnosed by surgical biopsy. Here we evaluate the perioperative status and postoperative complications of patients with pineal germinoma who underwent a primary biopsy or resection, treated according to SIOP CNS GCT 96. Methods: 235 patients[for full text, please go to the a.m. URL], 72. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Polnischen Gesellschaft für Neurochirurgie

Published
2021
Full Text
View/download PDF

40. Health-related quality of life in European childhood cancer survivors: Protocol for a study within PanCareLIFE

Author

Calaminus, G. (Gabriele), Baust, K. (Katja), Berger, C. (Claire), Byrne, J. (Julianne), Binder, H. (Harald), Casagranda, L. (Leonie), Grabow, D. (Desiree), Grootenhuis, M.A. (Martha), Kaatsch, P. (Peter), Kaiser, M. (Melanie), Kepak, T. (Tomas), Kepáková, K. (Kateřina), Kremer, L.C.M. (Leontien), Kruseova, J. (Jarmila), Luks, A. (Ales), Spix, C. (Claudia), van den Berg, M. (Marleen), Heuvel-Eibrink, M.M. (Marry) van den, van Dulmen-Den Broeder, E. (Eline), Kuonen, R. (Rahel), Sommer, G. (Grit), Kuehni, C. (Claudia), Grabow, D. (D.), Byrne, J. (J.), Campbell, H. (H.), Clissmann, C. (C.), O'Brien, K. (K.), Kremer, L.C.M. (L. C.M.), Langer, T. (T.), Dulmen-den Broeder, E. (Eline) van, Berg, M.H. (Marleen) van den, van den Heuvel-Eibrink, M.M. (M. M.), Borgmann-Staudt, A. (Anja), am Zehnhoff-Dinnesen, A. (A.), Haupt, R. (R.), Berger, C. (C.), Winther, J.F. (J. F.), Dirksen, U. (Uta), Calaminus, G. (Gabriele), Baust, K. (Katja), Berger, C. (Claire), Byrne, J. (Julianne), Binder, H. (Harald), Casagranda, L. (Leonie), Grabow, D. (Desiree), Grootenhuis, M.A. (Martha), Kaatsch, P. (Peter), Kaiser, M. (Melanie), Kepak, T. (Tomas), Kepáková, K. (Kateřina), Kremer, L.C.M. (Leontien), Kruseova, J. (Jarmila), Luks, A. (Ales), Spix, C. (Claudia), van den Berg, M. (Marleen), Heuvel-Eibrink, M.M. (Marry) van den, van Dulmen-Den Broeder, E. (Eline), Kuonen, R. (Rahel), Sommer, G. (Grit), Kuehni, C. (Claudia), Grabow, D. (D.), Byrne, J. (J.), Campbell, H. (H.), Clissmann, C. (C.), O'Brien, K. (K.), Kremer, L.C.M. (L. C.M.), Langer, T. (T.), Dulmen-den Broeder, E. (Eline) van, Berg, M.H. (Marleen) van den, van den Heuvel-Eibrink, M.M. (M. M.), Borgmann-Staudt, A. (Anja), am Zehnhoff-Dinnesen, A. (A.), Haupt, R. (R.), Berger, C. (C.), Winther, J.F. (J. F.), and Dirksen, U. (Uta)

Abstract

Background: Survival after childhood cancer has improved to more than 80% during the last few years, leading to an increased number of childhood cancer survivors. Cancer itself, or its treatment, may cause chronic health conditions, including somatic and mental sequelae, which may affect survivors’ health-related quality of life (HRQoL). Objective: The project PanCareLIFE aims to establish a large database with comprehensive data on childhood cancer survivors from different European countries, including data on HRQoL. Within PanCareLIFE, this study aims to describe HRQoL in survivors, investigate predictors of HRQoL, and describe the association of HRQoL with hearing and female fertility impairment. This paper describes the design of the HRQoL study, the origin of data, strategies for data collection, and sampling characteristics of survivors from each contributing country. Methods: A total of 6 institutions from 5 European countries (the Czech Republic, France, Germany, the Netherlands, and Switzerland) provided data on HRQoL assessed with the Short Form 36 and on relevant predictors. The central PanCareLIFE data center aggregated the data and harmonized the variables between the institutions. Survivors were eligible if they received a diagnosis of cancer according to the 12 main groups of the International Classification of Childhood Cancer, 3rd edition, or Langerhans cell histiocytosis; were aged ≤18 years at the time of diagnosis; were residents of the respective country at the time of diagnosis; had survived ≥5 years after cancer diagnosis; were aged ≥18 years at the time of the questionnaire survey; and did not refuse to registration in the national or local childhood cancer cohort. Results: We identified 24,993 eligible survivors. Of those, 19,268 survivors received a questionnaire and 9871 survivors participated, resulting in response rates of 9871/24,993 (39.50%) of eligible survivors and of 9871/19,268 (51.23%) invited survivors. Most participants were dia

Published
2021
Full Text
View/download PDF

41. TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study

Author

Meijer, A, Diepstraten, FA, Langer, T, Broer, L, Domingo, IK, Clemens, E, Uitterlinden, AG, de Vries, ACH, van Grotel, M, Vermeij, WP, Ozinga, RA, Binder, H, Byrne, J, van Dulmen-den Broeder, E, Garrè, ML, Grabow, D, Kaatsch, P, Kaiser, M, Kenborg, L, Falck-Winther, J, Rechnitzer, C, Hasle, H, Kepak, T, Kepakova, K, Tissing, WJE, van der Kooi, ALF, Kremer, LC, Kruseova, J, Pluijm, SMF, Kuehni, CF, van der Pal, H, Parfitt, R, Spix, C, Hesping, A, Deuster, D, Matulat, P, Calaminus, G, Hoetink, AE, Elsner, S, Gebauer, J, Haupt, R, Lackner, H, Blattmann, C, Neggers, SJCMM, Rassekh, SR, Wright, GEB, Brooks, B, Nagtegaal, AP, Drögemöller, BI, Ross, CJD, Bhavsar, AP, am Zehnhoff-Dinnesen, A, Carleton, BC, Zolk, O, van den Heuvel-Eibrink, M, Meijer, A, Diepstraten, FA, Langer, T, Broer, L, Domingo, IK, Clemens, E, Uitterlinden, AG, de Vries, ACH, van Grotel, M, Vermeij, WP, Ozinga, RA, Binder, H, Byrne, J, van Dulmen-den Broeder, E, Garrè, ML, Grabow, D, Kaatsch, P, Kaiser, M, Kenborg, L, Falck-Winther, J, Rechnitzer, C, Hasle, H, Kepak, T, Kepakova, K, Tissing, WJE, van der Kooi, ALF, Kremer, LC, Kruseova, J, Pluijm, SMF, Kuehni, CF, van der Pal, H, Parfitt, R, Spix, C, Hesping, A, Deuster, D, Matulat, P, Calaminus, G, Hoetink, AE, Elsner, S, Gebauer, J, Haupt, R, Lackner, H, Blattmann, C, Neggers, SJCMM, Rassekh, SR, Wright, GEB, Brooks, B, Nagtegaal, AP, Drögemöller, BI, Ross, CJD, Bhavsar, AP, am Zehnhoff-Dinnesen, A, Carleton, BC, Zolk, O, and van den Heuvel-Eibrink, M

Abstract

Background: Ototoxicity (hearing loss, tinnitus and/or vertigo) is a serious adverse event of cisplatin treatment in children with cancer. The heterogeneity in ototoxicity occurrence after similar treatment suggests a role for genetic susceptibility. This study investigated the association between carriership of novel single nucleotide polymorphisms (SNPs) and cisplatin-induced hearing loss (CIHL) in childhood cancer patients.Material and methods: The discovery cohort included cisplatin treated, non-cranial irradiated pediatric cancer patients within the European PanCareLIFE (PCL) study (N=390). CIHL at end of cancer treatment was defined as Muenster grade >=2b, assessed by pure tone audiometry. DNA was genotyped using the Infinium© Global Screening Array. Logistic regression models were applied including age at diagnosis, sex, cisplatin total cumulative dose and principal components 1-4, assuming an additive effect of the minor allele. Replication of the findings was performed in two independent, similarly treated cohorts (N=192 and N=188). Functional validation experiments in cultured human HeLa cell lines were performed to determine the effect of knockdown of the SNPs nearest identified gene on cisplatin-induced toxicity.Results: In the PCL discovery cohort, 8 SNPs reached a suggestive significance of P<1.0x10-5. One variant (rs893507) within the TCERG1L gene showed evidence of replication (P=0.01) in the Canadian first replication cohort. Analysis in the PCL second replication cohort confirmed this finding (P=1.0x10-4). The combined analysis showed that carriership of the C-allele of this newly discovered variant increases the odds of CIHL with 3.11-fold (P=5.3x10-10, 95% CI 2.2-4.5). Modulating TCERG1L expression significantly altered cell viability in response to cisplatin treatment, where TCERG1L overexpression and silencing protected and sensitized cells to cisplatin toxicity, respectively.Discussion: Children with cancer who carry a variant in the TCERG1L g

Published
2021

42. TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study

Author

Meijer, A. J.M., Diepstraten, F. A., Langer, T., Broer, L., Domingo, I. K., Clemens, E., Uitterlinden, A. G., de Vries, A. C.H., van Grotel, M., Vermeij, W. P., Ozinga, R. A., Binder, H., Byrne, J., van Dulmen-den Broeder, E., Garrè, M. L., Grabow, D., Kaatsch, P., Kaiser, M., Kenborg, L., Winther, J. F., Rechnitzer, C., Hasle, H., Kepak, T., Kepakova, K., Tissing, W. J.E., van der Kooi, A. L.F., Kremer, L. C.M., Kruseova, J., Pluijm, S. M.F., Kuehni, C. E., van der Pal, H. J.H., Parfitt, R., Spix, C., Tillmanns, A., Deuster, D., Matulat, P., Calaminus, G., Hoetink, A. E., Elsner, S., Gebauer, J., Haupt, R., Lackner, H., Blattmann, C., Neggers, S. J.C.M.M., Rassekh, S. R., Wright, G. E.B., Brooks, B., Nagtegaal, A. P., Drögemöller, B. I., Ross, C. J.D., Meijer, A. J.M., Diepstraten, F. A., Langer, T., Broer, L., Domingo, I. K., Clemens, E., Uitterlinden, A. G., de Vries, A. C.H., van Grotel, M., Vermeij, W. P., Ozinga, R. A., Binder, H., Byrne, J., van Dulmen-den Broeder, E., Garrè, M. L., Grabow, D., Kaatsch, P., Kaiser, M., Kenborg, L., Winther, J. F., Rechnitzer, C., Hasle, H., Kepak, T., Kepakova, K., Tissing, W. J.E., van der Kooi, A. L.F., Kremer, L. C.M., Kruseova, J., Pluijm, S. M.F., Kuehni, C. E., van der Pal, H. J.H., Parfitt, R., Spix, C., Tillmanns, A., Deuster, D., Matulat, P., Calaminus, G., Hoetink, A. E., Elsner, S., Gebauer, J., Haupt, R., Lackner, H., Blattmann, C., Neggers, S. J.C.M.M., Rassekh, S. R., Wright, G. E.B., Brooks, B., Nagtegaal, A. P., Drögemöller, B. I., and Ross, C. J.D.

Abstract

In children with cancer, the heterogeneity in ototoxicity occurrence after similar treatment suggests a role for genetic susceptibility. Using a genome-wide association study (GWAS) approach, we identified a genetic variant in TCERG1L (rs893507) to be associated with hearing loss in 390 non-cranial irradiated, cisplatin-treated children with cancer. These results were replicated in two independent, similarly treated cohorts (n = 192 and 188, respectively) (combined cohort: P = 5.3 × 10−10, OR 3.11, 95% CI 2.2–4.5). Modulating TCERG1L expression in cultured human cells revealed significantly altered cellular responses to cisplatin-induced cytokine secretion and toxicity. These results contribute to insights into the genetic and pathophysiological basis of cisplatin-induced ototoxicity.

Published
2021

43. Health-related quality of life in European childhood cancer survivors: Protocol for a study within PanCareLIFE

Author

Calaminus, G, Baust, K, Berger, C, Byrne, J, Binder, H, Casagranda, L, Grabow, D, Grootenhuis, M, Kaatsch, P, Kaiser, M, Kepak, T, Kepáková, K, Kremer, LC, Kruseova, J, Luks, A, Spix, C, van den Berg, M, Van den Heuvel - Eibrink, Marry, van Dulmen-Den Broeder, E, Kuonen, R, Sommer, G, Kuehni, C, Calaminus, G, Baust, K, Berger, C, Byrne, J, Binder, H, Casagranda, L, Grabow, D, Grootenhuis, M, Kaatsch, P, Kaiser, M, Kepak, T, Kepáková, K, Kremer, LC, Kruseova, J, Luks, A, Spix, C, van den Berg, M, Van den Heuvel - Eibrink, Marry, van Dulmen-Den Broeder, E, Kuonen, R, Sommer, G, and Kuehni, C

Abstract

Background: Survival after childhood cancer has improved to more than 80% during the last few years, leading to an increased number of childhood cancer survivors. Cancer itself, or its treatment, may cause chronic health conditions, including somatic and mental sequelae, which may affect survivors’ health-related quality of life (HRQoL). Objective: The project PanCareLIFE aims to establish a large database with comprehensive data on childhood cancer survivors from different European countries, including data on HRQoL. Within PanCareLIFE, this study aims to describe HRQoL in survivors, investigate predictors of HRQoL, and describe the association of HRQoL with hearing and female fertility impairment. This paper describes the design of the HRQoL study, the origin of data, strategies for data collection, and sampling characteristics of survivors from each contributing country. Methods: A total of 6 institutions from 5 European countries (the Czech Republic, France, Germany, the Netherlands, and Switzerland) provided data on HRQoL assessed with the Short Form 36 and on relevant predictors. The central PanCareLIFE data center aggregated the data and harmonized the variables between the institutions. Survivors were eligible if they received a diagnosis of cancer according to the 12 main groups of the International Classification of Childhood Cancer, 3rd edition, or Langerhans cell histiocytosis; were aged ≤18 years at the time of diagnosis; were residents of the respective country at the time of diagnosis; had survived ≥5 years after cancer diagnosis; were aged ≥18 years at the time of the questionnaire survey; and did not refuse to registration in the national or local childhood cancer cohort. Results: We identified 24,993 eligible survivors. Of those, 19,268 survivors received a questionnaire and 9871 survivors participated, resulting in response rates of 9871/24,993 (39.50%) of eligible survivors and of 9871/19,268 (51.23%) invited survivors. Most participants were

Published
2021

47. Langzeitüberlebende einer Krebserkrankung im Kindesalter: Heilung und Betreuung: Die Erice-Deklaration

Author

Haupt, R., Spinetta, J.J., Ban, I., Barr, R.D., Beck, J.D., Byrne, J., Calaminus, G., Coenen, E., Chesler, M., D’Angio, G.J., Eiser, C., Feldges, A., Gibson, F., Lackner, H., Masera, G., Massimo, L., Magyarosy, E., Otten, J., Reaman, G., Valsecchi, M.G., Veerman, A.J.P., Penn, A., Thorvildsen, A., von den Bos, C., Jankovic, M., and International Berlin-Frankfurt-Münster Study Group Early and Late Toxicity Educational Committee (I-BFM-SG ELTEC)

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results